July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Characteristics of Outer Choroidal Vessels in Eyes with Chronic Central Serous Chorioretinopathy Assessed by En Face Optical Coherence Tomography
Author Affiliations & Notes
  • Jun Takeuchi
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Keiko Kataoka
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Yuyako Nakano
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Ai Fujita
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Yasuki Ito
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Hiroko Terasaki
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
  • Footnotes
    Commercial Relationships   Jun Takeuchi, None; Keiko Kataoka, Bayer Health Care, Japan (R), Novartis Pharma K.K., Japan (R), Santen Pharmaceutical Co., Ltd, Japan (R); Yuyako Nakano, None; Ai Fujita, None; Yasuki Ito, Alcon Novartis Pharma, Japan (R), Bayer Health Care, Japan (R), Canon Life Care Solutions Inc., Japan (R), Carl Zeiss Meditec Co., Ltd., Japan (R), Kowa Pharmaceutical Company LTD., Japan (R), Pfizer Japan Inc., Japan (R), Santen Pharmaceutical Co., Ltd, Japan (R); Hiroko Terasaki, AbbVie GK, Japan (R), Alcon Pharma, Japan (F), AMO Japan K.K., Japan (F), Bayer Health Care, Japan (F), Carl Zeiss Meditec Co., Ltd., Japan (R), CHUO SANGIO Co., Ltd., Japan (R), DAIICHI SANKYO Co., Ltd., Japan (C), Eisai Co., Ltd., Japan (F), HOYA Corporation Ltd., Japan (F), Kowa Pharmaceutical Company Ltd., Japan (F), Mitsubishi Tanabe Pharma Corporation Ltd., Japan (R), NIDEK Co., Ltd., Japan (F), Nitten Pharmaceutical Co., Ltd., Japan (R), Otsuka Pharmaceutical Co., Ltd., Japan (F), Pfizer Japan Inc., Japan (F), ROHTO Pharmaceutical Co., Ltd., Japan (F), Sanofi K.K., Japan (R), Santen Pharmaceutical Co., Ltd, Japan (F), Senju Pharmaceutical Co., Ltd., Japan (F), Tomey Corporation Ltd., Japan (F), WAKAMOTO Co., Ltd., Japan (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5048. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jun Takeuchi, Keiko Kataoka, Yuyako Nakano, Ai Fujita, Yasuki Ito, Hiroko Terasaki; Characteristics of Outer Choroidal Vessels in Eyes with Chronic Central Serous Chorioretinopathy Assessed by En Face Optical Coherence Tomography. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5048.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Central serous chorioretinopathy (CSC) is characterized by choroidal thickening mainly due to pathologic dilatation of outer choroidal vessels. Recently, it was reported that most vortex veins in the eyes of acute CSC show vertically asymmetric, and more than three-fourths of those eyes had dominant vortex veins extended beyond macula region. This study aimed to evaluate the outer choroidal vessels in eyes with chronic CSC.

Methods : This retrospective study collected 48 eyes of 48 patients with treatment naïve chronic CSC. 12 × 12 scan area of Swept-source optical coherence tomography (PLEX Elite 9000, AngioPlex, Zeiss) were performed in all patients to obtain en face images of the posterior pole in addition to complete ophthalmic examination including indocyanine green angiography. We manually chose the slab containing Haller vessel and Sattler vessel to construct en face images. Three independent investigators examined all the en face images and classified them into 2 groups: the symmetry group with vertical symmetric outer choroidal vessels and the asymmetry group with vertical asymmetric outer choroidal vessels. The asymmetry group was further classified into 3 grades according to how far the dominant vortex vein extends: the macular region (grade 1), the posterior pole (grade 2), or beyond the vascular arcades (grade 3). The excluding criteria was the defective en face image due to severe cataract or excess motion artifacts.

Results : The mean age was 58.31 ± 13.20 years (range 36-83 years), and 38 subjects (79.2%) were male. The mean axial length was 23.80 ± 1.15 mm (range 21.90-26.83 mm, unknown in 3 subjects), and the mean symptom duration to diagnosis was 38.02 ± 51.02 months (range 4-234 months, unknown in 4 subjects). Of total 48 chronic CSC eyes,14 eyes (29.2%) were classified into the symmetry group, and 34 eyes (70.8%) were classified into the asymmetry group. In the asymmetry group, 23 eyes were classified as grade 1, 5 eyes as grade 2, and 6 eyes as grade 3.

Conclusions : Almost 30% of chronic CSC has vertical symmetric outer choroidal vessels. Even in the asymmetry group, only 32.4% eyes had dominant vortex veins extending beyond macula region (grade 2 + grade 3). It suggests that as CSC becomes chronic, the blood flow of dilated dominant vortex veins may be compensated by the contralateral vortex veins.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×